Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7133980 | 0.86 | NPC1 (0.60) | MDM2RETPLK4PLK1NPC1 | |
| SCHEMBL5358951 | 0.85 | MDM2 (0.47) | PTPN1MDM2PLK4PLK1NPC1 | |
| SCHEMBL5358356 | 0.85 | AR (0.52) | MDM2LRRK2 | |
| SCHEMBL5366869 | 0.85 | IGF1R (0.56) | RETPLK4PLK1RAF1NTRK1 | |
| SCHEMBL5367274 | 0.84 | MEN1 (0.53) | MDM2RETPLK4PLK1NPC1 | |
| SCHEMBL7135671 | 0.82 | SIRT1 (0.46) | MDM2PLK4PLK1RAF1LRRK2 | |
| SCHEMBL7140043 | 0.82 | PTPN1 (0.49) | PTPN1MDM2RETCES2PLK4 | |
| SCHEMBL5363581 | 0.81 | ERN1 (0.48) | RETPLK4PLK1RAF1NTRK1 | |
| SCHEMBL7134847 | 0.81 | KDM1A (0.58) | RETPLK4PLK1CDK2 | |
| SCHEMBL5361530 | 0.81 | LRRK2 (0.49) | MDM2RETPLK4NTRK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PTPN1 882/4885MDM2 888/4885RET 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.